**Supplement material**

S1 Table. Baseline cytokine levels in PCM overdosed patients compared to healthy controls. PCM, paracetamol. IL-6, interleukin-6, IL-1β, interleukin-1β, TNF-α, Tumor necrosis factor-alfa, IL-13, interleukin-13, IFN-γ, interferon-gamma

|  |  |  |  |
| --- | --- | --- | --- |
|  | PCM cohort | Controls | P |
| IL-6 (ρg/mL) | 1.6 (0.6 – 2.3) | 0.7 (0.4 – 1.3) | 0.12 |
| IL-1β (ρg/mL) | 0.06 (0 – 0.13) | 0.03 (0 – 0.07) | 0.43 |
| TNF-α (ρg/mL) | 2.0 (1.7 – 2.7) | 2.0 (1.5 – 2.3) | 0.45 |
| IL-13 (ρg/mL) | 0.7 (0 – 1.2) | 0.7 (0 – 1.3) | 0.97 |
| IFN-γ (ρg/mL) | 4.6 (2.9 – 8.2) | 3.5 (3.1 – 5.1) | 0.45 |

S2 table. Baseline levels of soluble CD163, soluble mannose receptor and alanine transaminase in the two patients from the Aarhus cohort presenting with elevated bilirubin levels.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Bilirubin (µmol/L) | ALT (IU/L) | sCD163 (mg/L) | sMR (mg/L) |
| Patient 1 | 34 | 17523 | 11.35 | 0.775 |
| Patient 2 | 46 | 7000 | 6.7 | 0.495 |

Units are in parenthesis. ALT, alanine transaminase; sCD163 soluble CD163; sMR, soluble mannose receptor.

S3A figure. Change in soluble CD163 levels during treatment with N-Acetylcysteine in patients from the Aarhus cohort compared to healthy controls. sCD163, soluble CD163; ALT, alanine transaminase.



S3B figure. Change in soluble mannose receptor levels during treatment with N-Acetylcysteine in patients from the Aarhus cohort compared to healthy controls. sMR, soluble mannose receptor; ALT, alanine transaminase.

